Immuron Limited

Buy Online

Protectyn®

Protectyn® is a very special form of colostrum that is naturally boosted with antibodies and other components to protect infants from diseases of the digestive system....

Travelan®

Travelan® is an over-the-counter oral polyclonal antibody therapy that helps reduce the risk of Travellers’ Diarrhoea when you are travelling overseas....

Immuron files FDA application for deadly C. diff infection fight

8 July 2024

Immuron has filed a pre-investigational new drug application with the United States Food and Drug Ad...

Immuron Ltd Newsletter (June 2024)

1 June 2024

Immuron Ltd newsletter June 2024. Updates on milesone achievements, sales, and general Immuron Ltd n...

Biotech Daily: Dr Boreham’s Crucible: Immuron

10 May 2024

Immuron is in the throes of multiple clinical trials to prove the efficacy of Travelan against speci...

The Watchlist: Immuron's Travelan sales growth, clinical pipeline achievements and upcoming milestones!

26 April 2024

CEO Steve Lydeamore provides an update on Travelan's exponential growth!...

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4854
Fax: +613 9899 8533

Travelan®

Protectyn®

Record half yearly Travelan® sales

Buy Online

Protectyn®

Travelan®

Clinical Insights & Updates

Travelan® clinical study resulting in up to 90% efficacy in prevention of travelers’ diarrhea

IMM-529 pre-clinical study indicates protection against C.diff infection and disease recurrence

Immuron poster presentation at Military Health System Research Symposium 2023

Recent Articles

Immuron files FDA application for deadly C. diff infection fight

Immuron Ltd Newsletter (June 2024)

Biotech Daily: Dr Boreham’s Crucible: Immuron

The Watchlist: Immuron's Travelan sales growth, clinical pipeline achievements and upcoming milestones!

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information